MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 11:00:03 27/06/2024 BST | ||
| 18.8 EUR / 19 EUR | +0.53% |
|
| Current month | +11.05% | ||
| 1 month | +9.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 18.9 | +0.53% |
| 26/06/24 | 18.8 | +0.05% |
| 25/06/24 | 18.79 | -0.53% |
| 24/06/24 | 18.89 | +3.22% |
| 21/06/24 | 18.3 | -1.45% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 08:42 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD7XY1 |
| ISIN | DE000MD7XY18 |
| Date issued | 06/09/2022 |
| Strike | 272.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.23 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.79 € |
|---|---|
| Lowest since issue | 4.09 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
